Overdoses Involving Xylazine Mixed with Fentanyl: Clinical and Public Health Implications

Details

• Personal Author:
  Arwady, Allison ; Schier, Josh ; Nelson, Lewis S.
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.). Office of Communications. ; National Center for Injury Prevention and Control (U.S.). Division of Overdose Prevention. ; Rutgers New Jersey Medical School. Department of Emergency Medicine. Division of Medical Toxicology and Addiction Medicine.
• Description:
  The non-opioid drug xylazine has been found in the U.S. illegal drug supply and is associated with overdose deaths from fentanyl. Xylazine is not approved for use in people and can cause sedation and other adverse health effects. During this COCA Call, presenters will discuss the epidemiology of overdoses involving xylazine mixed with fentanyl, the current understanding of health risks related to these overdoses, and acute treatment strategies. Presenters will also review the state of laboratory testing, outline potential harm reduction activities, and provide an example of an ongoing public health and clinical partnership to mitigate harms from xylazine mixed with fentanyl.
  
  022924_slides.pdf
  
  
• Subjects:
  Drug Overdose Fentanyl Opiate Overdose Xylazine
• Series:
  Clinician Outreach and Communication Activity (COCA) Call
• Document Type:
  Text
• Genre:
  Presentation
• Pages in Document:
  65 unnumbered slides
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha-512:dd8e174bfd786295522a64ead7991418d1411d387e5842dcd92c7d2776c06cc6002a4ded653e687f12e882caff7d4b26f45a2df13c7ba338f70663ccd9ba936a
• Download URL:
  https://stacks.cdc.gov/view/cdc/156536/cdc_156536_DS1.pdf
• File Type:
  [PDF - 4.67 MB ]